A Phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC

被引：0
|
作者：
Kim, Miso [1 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul, South Korea
来源：
ONCOLOGIST | 2024年 / 29卷
关键词：
Fianlimab; cemiplimab; advanced clear cell renal cell carcinoma;
D O I：
10.1093/oncolo/oyae181.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [41] Initial Efficacy of Anti-Lymphocyte Activation Gene-3 (Anti-LAG-3; BMS-986016) in Combination with Nivolumab in Patients with Melanoma WHO Progressed During Prior Anti-PD-1/PD-L1 Therapy
    Ascierto, Paulo A.
    Melero, Ignacio
    Bhatia, Shailender
    Bono, Petri
    Sanborn, Rachel E.
    Lipson, Evan J.
    Callahan, Margaret K.
    Gajewski, Thomas
    Gomez-Roca, Carlos A.
    Hodi, F. Stephen
    Curigliano, Giuseppe
    Nyakas, Marta
    Preusser, Matthias
    Koguchi, Yoshinobu
    Maurer, Matthew
    Harbison, Christopher
    Mitra, Priyam
    Suryawanshi, Satyendra
    Munoz-Couselo, Eva
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 114 - 114
  • [42] Combined treatment with anti-LAG-3 and anti-PD-1 fully human monoclonal antibodies inhibits tumor growth in immunocompetent double humanized LAG-3/PD-1 mice
    Burova, Elena
    Allbritton, Omaira
    Taduriyasas, Chandrika
    Lai, Venus
    Poueymirou, William
    Papadopoulos, Nicholas
    MacDonald, Douglas
    Olson, William
    Mohrs, Markus
    Ioffe, Ella
    Thurston, Gavin
    CANCER RESEARCH, 2016, 76
  • [43] Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma
    Pasek, Marek
    Sticova, Eva
    Marques, Emanuel
    Tretera, Vojtech
    Arenberger, Petr
    Arenbergerova, Monika
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2025, 15 (01):
  • [44] LAG-3 expression after anti-PD-1 treatment
    Geraldes, Flavia Oliveira
    LANCET ONCOLOGY, 2021, 22 (12): : 1655 - 1655
  • [45] A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDY OF INCA32459, A BISPECIFIC ANTI-PD1 AND ANTI-LAG-3 ANTIBODY, IN PATIENTS WITH SELECT ADVANCED MALIGNANCIES
    Piha-Paul, Sarina
    Bourayou, Nawel
    Schaub, Richard
    Yang, Yan-ou
    Wei, Wendy
    Mayes, Patrick
    Gangadhar, Tara
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A756 - A756
  • [46] Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanc
    Cho, Byoung Chul
    Dy, Grace K.
    Kim, Tae Min
    Sarker, Debashis
    Hamid, Omid
    Williamson, Stephen K.
    Kim, Sang -We
    Husain, Hatim
    Fang, Fang
    Chen, Shuquan
    Mani, Jayakumar
    Jankovic, Vladimir
    Paccaly, Anne
    Masinde, Sheila
    Lowy, Israel
    Brennan, Laura
    Salvati, Mark
    Fury, Matthew
    Lewis, Karl
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E8 - E9
  • [47] A PHASE I/II STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS
    Lakhani, Nehal
    Johnson, Melissa
    Groisberg, Roman
    Han, Hyunsil
    Casey, Kerry
    Li, Siyu
    Skokos, Dimitris
    Seebach, Frank
    Lowy, Israel
    Fury, Matthew
    Mathias, Melissa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A565 - A565
  • [48] Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study.
    Timmerman, John
    Lavie, David
    Johnson, Nathalie A.
    Avigdor, Abraham
    Borchmann, Peter
    Andreadis, Charalambos
    Bazargan, Ali
    Gregory, Gareth
    Keane, Colm
    Inna, Tzoran
    Vucinic, Vladan
    Zinzani, Pier Luigi
    Zhang, Hong
    Pillai, Pallavi
    Marinello, Patricia
    Herrera, Alex Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors
    Tolcher, Anthony
    Hafez, Navid
    Yamamoto, Noboru
    Park, Jaehong
    Grempler, Rolf
    Lucarelli, Anthony
    Vallaster, Markus P.
    Wang, Bushi
    Hyman, David
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [50] IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM
    Jackson, Christina
    Choi, John
    Zhang, JiaJia
    Piotrowski, Anna
    Walbert, Tobias
    Desai, Arati
    Ahluwalia, Manmeet
    Nabors, Burt
    Ye, Xiaobu
    Desideri, Serena
    Fisher, Joy
    Wen, Patrick
    Grossman, Stuart
    Smith, Kellie
    Pardoll, Drew
    Lim, Michael
    NEURO-ONCOLOGY, 2019, 21 : 122 - 122
12345